What is VitaCyte?
VitaCyte is a specialized biotechnology firm focused on the manufacturing and supply of GMP Grade purified-defined collagenase and protease enzymes. These critical reagents are essential for cell and tissue dissociation, serving researchers, commercial cell suppliers, and institutions engaged in cell therapy and the manufacturing of therapeutic agents. The company distinguishes itself through custom manufacturing capabilities, offering tailored enzyme formulations to meet precise application requirements. VitaCyte's commitment to high-quality, lot-to-lot consistency aims to accelerate advancements in cell isolation and transplantation technologies, positioning it as a key player in the life sciences supply chain.
How much funding has VitaCyte raised?
VitaCyte has raised a total of $143K across 1 funding round:
Debt
$143K
Debt (2021): $143K with participation from PPP
What's next for VitaCyte?
With the recent influx of capital, VitaCyte is poised for accelerated growth and expanded market reach. The 'large-scale late-stage funding' suggests a strategic focus on scaling operations, enhancing production capacity, and potentially broadening its product portfolio or research and development initiatives. This investment will likely enable VitaCyte to further solidify its position as a leading supplier of critical enzymes for cell therapy and regenerative medicine, driving innovation in therapeutic agent manufacturing and supporting the advancement of cell-based treatments.
See full VitaCyte company page
